Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Century Therapeutics (IPSC) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 67.95%.

  • Century Therapeutics' EBIT Margin rose 37298200.0% to 67.95% in Q1 2025 from the same period last year, while for Sep 2025 it was 29.91%, marking a year-over-year increase of 53561300.0%. This contributed to the annual value of 2096.48% for FY2024, which is 44603900.0% up from last year.
  • According to the latest figures from Q1 2025, Century Therapeutics' EBIT Margin is 67.95%, which was up 37298200.0% from 893.46% recorded in Q4 2024.
  • Century Therapeutics' EBIT Margin's 5-year high stood at 67.95% during Q1 2025, with a 5-year trough of 35431.31% in Q2 2023.
  • For the 4-year period, Century Therapeutics' EBIT Margin averaged around 8053.42%, with its median value being 3661.87% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -331855400bps in 2023, then soared by 309235300bps in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' EBIT Margin stood at 6392.71% in 2022, then tumbled by -155bps to 16329.1% in 2023, then soared by 95bps to 893.46% in 2024, then skyrocketed by 108bps to 67.95% in 2025.
  • Its EBIT Margin stands at 67.95% for Q1 2025, versus 893.46% for Q4 2024 and 4398.1% for Q3 2024.